{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:36:59Z","timestamp":1792089419636,"version":"4.4.0"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40264-025-01596-9","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T17:35:53Z","timestamp":1754760953000},"page":"27-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0938-2964","authenticated-orcid":false,"given":"Emile","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Weddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dannelle","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"issue":"1\u20132","key":"1596_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hum.2023.29263.bfs","volume":"35","author":"A Philippidis","year":"2024","unstructured":"Philippidis A. CASGEVY makes history as FDA approves first CRISPR\/Cas9 genome edited therapy. Hum Gene Ther. 2024;35(1\u20132):1\u20134.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"1596_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ajh.26741","volume":"98","author":"J Kanter","year":"2023","unstructured":"Kanter J, et al. Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am J Hematol. 2023;98(1):11\u201322.","journal-title":"Am J Hematol"},{"key":"1596_CR3","unstructured":"U.S. Food and Drug Administration, FDA approves first gene therapies to treat patients with sickle cell disease. FDA.gov. 2023."},{"key":"1596_CR4","unstructured":"U.S. Food and Drug Administration, FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma. FDA.gov. 2024."},{"key":"1596_CR5","doi-asserted-by":"publisher","first-page":"1490491","DOI":"10.3389\/fimmu.2025.1490491","volume":"16","author":"X Ye","year":"2025","unstructured":"Ye X, et al. CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security? Front Immunol. 2025;16:1490491.","journal-title":"Front Immunol"},{"issue":"1","key":"1596_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47801-8","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi M, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun. 2024;15(1): 3371.","journal-title":"Nat Commun"},{"key":"1596_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","volume":"45","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, et al. Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 2022;45:891\u2013908.","journal-title":"Drug Saf"},{"issue":"8","key":"1596_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","volume":"45","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, et al. Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 2022;45(8):891\u2013908.","journal-title":"Drug Saf"},{"issue":"14","key":"1596_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Delandistrogene moxeparvovec: first approval. Drugs. 2023;83(14):1323\u20139.","journal-title":"Drugs"},{"issue":"10322","key":"1596_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli F, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet. 2022;399(10322):372\u201383.","journal-title":"Lancet"},{"issue":"13","key":"1596_CR11","first-page":"1427","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Eladocagene exuparvovec: first approval. Drugs. 2022;82(13):1427\u201332.","journal-title":"Drugs"},{"issue":"3","key":"1596_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, et al. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1596_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5644","key":"1596_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415\u20139.","journal-title":"Science"},{"issue":"9","key":"1596_CR15","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1172\/JCI35798","volume":"118","author":"SJ Howe","year":"2008","unstructured":"Howe SJ, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Investig. 2008;118(9):3143\u201350.","journal-title":"J Clin Investig"},{"issue":"12","key":"1596_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","volume":"390","author":"DX Bharucha-Goebel","year":"2024","unstructured":"Bharucha-Goebel DX, et al. Intrathecal gene therapy for giant axonal neuropathy. N Engl J Med. 2024;390(12):1092\u2013104.","journal-title":"N Engl J Med"},{"issue":"7","key":"1596_CR17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/ner.13325","volume":"24","author":"V Goel","year":"2021","unstructured":"Goel V, et al. Adverse events and complications associated with intrathecal drug delivery systems: insights from the manufacturer and user facility device experience (MAUDE) database. Neuromodulation. 2021;24(7):1181\u20139.","journal-title":"Neuromodulation"},{"issue":"2","key":"1596_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","volume":"25","author":"DL Wagner","year":"2019","unstructured":"Wagner DL, et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med. 2019;25(2):242\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"1596_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249\u201354.","journal-title":"Nat Med"},{"issue":"5","key":"1596_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1590\/S0100-879X2007000500002","volume":"40","author":"BE Strauss","year":"2007","unstructured":"Strauss BE, Costanzi-Strauss E. Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency. Braz J Med Biol Res. 2007;40(5):601\u201313.","journal-title":"Braz J Med Biol Res"},{"issue":"18","key":"1596_CR21","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMp2200089","volume":"386","author":"J Concato","year":"2022","unstructured":"Concato J, Corrigan-Curay J. Real-world evidence - where are we now? N Engl J Med. 2022;386(18):1680\u20132.","journal-title":"N Engl J Med"},{"key":"1596_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01536-7","author":"H Le","year":"2025","unstructured":"Le H, et al. Understanding the work of the Pharmacovigilance Risk Assessment Committee (PRAC): a quantitative review of the post-authorisation safety evaluation of antidiabetic drugs from 2012 to 2022. Drug Saf. 2025. https:\/\/doi.org\/10.1007\/s40264-025-01536-7.","journal-title":"Drug Saf"},{"issue":"8708","key":"1596_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0140-6736(90)91669-2","volume":"336","author":"IR Edwards","year":"1990","unstructured":"Edwards IR, et al. Quality criteria for early signals of possible adverse drug reactions. Lancet. 1990;336(8708):156\u20138.","journal-title":"Lancet"},{"issue":"4","key":"1596_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"1596_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100800","volume":"13","author":"M Laurent","year":"2024","unstructured":"Laurent M, et al. CRISPR-based gene therapies: from preclinical to clinical treatments. Cells. 2024;13(10): 800.","journal-title":"Cells"},{"key":"1596_CR26","doi-asserted-by":"publisher","DOI":"10.2196\/57824","volume":"26","author":"S Dimitsaki","year":"2024","unstructured":"Dimitsaki S, Natsiavas P, Jaulent MC. Applying AI to structured real-world data for pharmacovigilance purposes: scoping review. J Med Internet Res. 2024;26: e57824.","journal-title":"J Med Internet Res"},{"key":"1596_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1527600","author":"E Youssef","year":"2025","unstructured":"Youssef E, Fletcher B, Palmer D. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Front Med. 2025. https:\/\/doi.org\/10.3389\/fmed.2024.1527600.","journal-title":"Front Med"},{"key":"1596_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060940","author":"E Youssef","year":"2025","unstructured":"Youssef E, et al. Exosomes in precision oncology and beyond: from bench to bedside in diagnostics and therapeutics. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17060940.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1596_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1596_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664\u201379.","journal-title":"Cancer Discov"},{"issue":"21","key":"1596_CR31","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u2013306.","journal-title":"Blood"},{"issue":"2","key":"1596_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.htct.2022.08.002","volume":"45","author":"V Hungria","year":"2023","unstructured":"Hungria V, et al. CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil. Hematol Transfus Cell Ther. 2023;45(2):266\u201374.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"35","key":"1596_CR33","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978\u201392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1596_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1): 56.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1596_CR35","doi-asserted-by":"publisher","first-page":"9228","DOI":"10.1002\/cam4.5665","volume":"12","author":"MZ Powell","year":"2023","unstructured":"Powell MZ, et al. Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients. Cancer Med. 2023;12(8):9228\u201335.","journal-title":"Cancer Med"},{"issue":"20","key":"1596_CR36","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430\u201342.","journal-title":"Blood"},{"issue":"1","key":"1596_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5209","volume":"10","author":"RM Mart\u00edn-Rojas","year":"2022","unstructured":"Mart\u00edn-Rojas RM, et al. Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel. Clin Case Rep. 2022;10(1): e05209.","journal-title":"Clin Case Rep"},{"key":"1596_CR38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"RD Sandler","year":"2020","unstructured":"Sandler RD, et al. Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020;11:524.","journal-title":"Front Immunol"},{"key":"1596_CR39","doi-asserted-by":"publisher","first-page":"e000746","DOI":"10.1136\/esmoopen-2020-000746","volume":"4","author":"L Y\u00e1\u00f1ez","year":"2020","unstructured":"Y\u00e1\u00f1ez L, et al. How I treat adverse effects of CAR-T cell therapy. ESMO Open. 2020;4:e000746.","journal-title":"ESMO Open"},{"issue":"12","key":"1596_CR40","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u201319.","journal-title":"Cancer Discov"},{"issue":"3","key":"1596_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/CCM.0b013e3182a66b76","volume":"42","author":"C Traube","year":"2014","unstructured":"Traube C, et al. Cornell assessment of pediatric delirium: a valid, rapid, observational tool for screening delirium in the PICU. Crit Care Med. 2014;42(3):656\u201363.","journal-title":"Crit Care Med"},{"key":"1596_CR42","doi-asserted-by":"crossref","unstructured":"CADTH Health Technology Review, in Anticytokine therapy and corticosteroids for cytokine release syndrome and for neurotoxicity following T-cell engager or CAR T-cell therapy: rapid review. 2024, Canadian Agency for Drugs and Technologies in Health: Ottawa (ON).","DOI":"10.51731\/cjht.2024.884"},{"issue":"10","key":"1596_CR43","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","volume":"6","author":"F Schoeberl","year":"2022","unstructured":"Schoeberl F, et al. Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. Blood Adv. 2022;6(10):3022\u20136.","journal-title":"Blood Adv"},{"key":"1596_CR44","doi-asserted-by":"crossref","unstructured":"Schulenburg A et al. S100 as marker for immune effector cell-associated neurotoxicity syndrome. Wiener klinische Wochenschrift. 2024.","DOI":"10.1007\/s00508-024-02451-0"},{"issue":"22","key":"1596_CR45","first-page":"2109","volume":"248","author":"V Gayger-Dias","year":"2023","unstructured":"Gayger-Dias V, et al. How S100B crosses brain barriers and why it is considered a peripheral marker of brain injury. Exp Biol Med (Maywood). 2023;248(22):2109\u201319.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1596_CR46","doi-asserted-by":"crossref","unstructured":"Stutterheim J et al. KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges. Haematologica. 2025.","DOI":"10.3324\/haematol.2024.285642"},{"issue":"9","key":"1596_CR47","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2025","unstructured":"Gupta S, et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392(9):875\u201391.","journal-title":"N Engl J Med"},{"key":"1596_CR48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, et al. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433\u201344.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"1596_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13054-024-04851-0","volume":"28","author":"M Bellal","year":"2024","unstructured":"Bellal M, et al. Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update. Crit Care. 2024;28(1):69.","journal-title":"Crit Care"},{"key":"1596_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879608","volume":"13","author":"RC Sterner","year":"2022","unstructured":"Sterner RC, Sterner RM. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front Immunol. 2022;13: 879608.","journal-title":"Front Immunol"},{"issue":"6","key":"1596_CR51","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.hoc.2023.05.010","volume":"37","author":"R Epperly","year":"2023","unstructured":"Epperly R, et al. Early and late toxicities of chimeric antigen receptor T-cells. Hematol Oncol Clin North Am. 2023;37(6):1169\u201388.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"S1","key":"1596_CR52","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.5045\/br.2023.2023026","volume":"58","author":"JW Yoo","year":"2023","unstructured":"Yoo JW. Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Blood Res. 2023;58(S1):S20-s28.","journal-title":"Blood Res"},{"issue":"9","key":"1596_CR53","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.3390\/biomedicines10092286","volume":"10","author":"D Ragoonanan","year":"2022","unstructured":"Ragoonanan D, et al. The evolution of chimeric antigen receptor T-cell therapy in children, adolescents and young adults with acute lymphoblastic leukemia. Biomedicines. 2022;10(9):2286.","journal-title":"Biomedicines"},{"key":"1596_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101272","author":"S Pagliuca","year":"2025","unstructured":"Pagliuca S, et al. The landscape of immune monitoring in CAR-T cell therapy: a comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT. Blood Rev. 2025. https:\/\/doi.org\/10.1016\/j.blre.2025.101272.","journal-title":"Blood Rev"},{"issue":"26","key":"1596_CR55","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"key":"1596_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"1","key":"1596_CR57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"1596_CR58","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023;29(7):438.e1-438.e16.","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"1596_CR59","first-page":"438.e1","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl Cell Ther Off Publ Am Soc Transpl Cell Ther. 2023;29(7):438.e1-438.e16.","journal-title":"Transpl Cell Ther Off Publ Am Soc Transpl Cell Ther"},{"key":"1596_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215149","author":"T Fugere","year":"2023","unstructured":"Fugere T, et al. Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15215149.","journal-title":"Cancers (Basel)"},{"key":"1596_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06336-8","author":"X Lan","year":"2025","unstructured":"Lan X, et al. CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone). Ann Hematol. 2025. https:\/\/doi.org\/10.1007\/s00277-025-06336-8.","journal-title":"Ann Hematol"},{"key":"1596_CR62","doi-asserted-by":"publisher","first-page":"769802","DOI":"10.3389\/fimmu.2021.769802","volume":"12","author":"S Gong","year":"2021","unstructured":"Gong S, et al. Urinary soluble CD163 levels predict IgA nephropathy remission status. Front Immunol. 2021;12:769802.","journal-title":"Front Immunol"},{"key":"1596_CR63","first-page":"1254","volume":"110","author":"O Beyar-Katz","year":"2025","unstructured":"Beyar-Katz O, Rejeski K, Shouval R. Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies. Haematologica. 2025;110:1254.","journal-title":"Haematologica"},{"issue":"6","key":"1596_CR64","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, et al. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 2024;11(6):e459\u201370.","journal-title":"Lancet Haematol"},{"issue":"5","key":"1596_CR65","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","volume":"59","author":"M Mohan","year":"2024","unstructured":"Mohan M, et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024;59(5):647\u201352.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"1596_CR66","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00277-017-2993-y","volume":"96","author":"M Lin","year":"2017","unstructured":"Lin M, et al. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017;96(8):1241\u201351.","journal-title":"Ann Hematol"},{"issue":"1","key":"1596_CR67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40164-023-00435-w","volume":"12","author":"C Aparicio","year":"2023","unstructured":"Aparicio C, Acebal C, Gonz\u00e1lez-Vallinas M. Current approaches to develop \u201coff-the-shelf\u201d chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review. Exp Hematol Oncol. 2023;12(1):73.","journal-title":"Exp Hematol Oncol"},{"issue":"18","key":"1596_CR68","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot L, et al. Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive t-cell immunotherapies. Cancer Res. 2015;75(18):3853\u201364.","journal-title":"Cancer Res"},{"issue":"2","key":"1596_CR69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"1596_CR70","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137.","journal-title":"Oncologist"},{"issue":"2","key":"1596_CR71","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","volume":"3","author":"KO McNerney","year":"2022","unstructured":"McNerney KO, et al. Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy. Blood Cancer Discov. 2022;3(2):90\u20134.","journal-title":"Blood Cancer Discov"},{"key":"1596_CR72","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.omtm.2020.12.008","volume":"20","author":"J Alzubi","year":"2021","unstructured":"Alzubi J, et al. Automated generation of gene-edited CAR T cells at clinical scale. Mol Ther Methods Clin Dev. 2021;20:379\u201388.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1596_CR73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exphem.2022.03.002","volume":"110","author":"W Wen","year":"2022","unstructured":"Wen W, Zhang X-B. CRISPR\u2013Cas9 gene editing induced complex on-target outcomes in human cells. Exp Hematol. 2022;110:13\u20139.","journal-title":"Exp Hematol"},{"issue":"8","key":"1596_CR74","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765\u201371.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1596_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25414-9","volume":"12","author":"VL Simhadri","year":"2021","unstructured":"Simhadri VL, et al. Cas9-derived peptides presented by MHC class II that elicit proliferation of CD4+ T-cells. Nat Commun. 2021;12(1): 5090.","journal-title":"Nat Commun"},{"issue":"4","key":"1596_CR76","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11901-023-00624-5","volume":"22","author":"B Jagadisan","year":"2023","unstructured":"Jagadisan B, Dhawan A. Hepatotoxicity in adeno-associated viral vector gene therapy. Curr Hepatol Rep. 2023;22(4):276\u201390.","journal-title":"Curr Hepatol Rep"},{"key":"1596_CR77","doi-asserted-by":"crossref","unstructured":"McNally EM. Improving the safety of systemic viral gene therapy. J Clin Invest. 2024;134(1):e177078.","DOI":"10.1172\/JCI177078"},{"key":"1596_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020282","author":"A Bangolo","year":"2025","unstructured":"Bangolo A, et al. Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17020282.","journal-title":"Cancers (Basel)"},{"issue":"20","key":"1596_CR79","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How i treat cytopenias after CAR T-cell therapy. Blood. 2023;141(20):2460\u20139.","journal-title":"Blood"},{"issue":"2","key":"1596_CR80","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","volume":"10","author":"J Wat","year":"2022","unstructured":"Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract. 2022;10(2):460\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"1596_CR81","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/bloodadvances.2022008066","volume":"7","author":"G Drillet","year":"2023","unstructured":"Drillet G, et al. Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists. Blood Adv. 2023;7(4):537\u201340.","journal-title":"Blood Adv"},{"issue":"2","key":"1596_CR82","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11684-023-1032-8","volume":"18","author":"S Zhang","year":"2024","unstructured":"Zhang S, et al. EBV-associated lymphoproliferative disease post-CAR-T cell therapy. Front Med. 2024;18(2):394\u20138.","journal-title":"Front Med"},{"key":"1596_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1398078","volume":"14","author":"S Arya","year":"2024","unstructured":"Arya S, Shahid Z. Overview of infectious complications among CAR T- cell therapy recipients. Front Oncol. 2024;14: 1398078.","journal-title":"Front Oncol"},{"key":"1596_CR84","doi-asserted-by":"publisher","first-page":"1404351","DOI":"10.3389\/fonc.2024.1404351","volume":"14","author":"AC Cordeiro","year":"2024","unstructured":"Cordeiro AC, et al. Late events after anti-CD19 CAR T-cell therapy for relapsed\/refractory B-cell non-Hodgkin lymphoma. Front Oncol. 2024;14:1404351.","journal-title":"Front Oncol"},{"issue":"9","key":"1596_CR85","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM dos Cordas Santos","year":"2024","unstructured":"dos Cordas Santos DM, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30(9):2667\u201378.","journal-title":"Nat Med"},{"issue":"10","key":"1596_CR86","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn K, Perales M-A. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2022;57(10):1477\u201388.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1596_CR87","volume":"2012","author":"G Romano","year":"2012","unstructured":"Romano G. Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. Int Sch Res Not. 2012;2012(1): 616310.","journal-title":"Int Sch Res Not"},{"key":"1596_CR88","volume":"2012","author":"G Romano","year":"2012","unstructured":"Romano G. Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. ISRN Oncol. 2012;2012: 616310.","journal-title":"ISRN Oncol"},{"issue":"21\u201322","key":"1596_CR89","first-page":"1126","volume":"33","author":"JS Moffit","year":"2022","unstructured":"Moffit JS, et al. Regulatory consideration for the nonclinical safety assessment of gene therapies. Hum Gene Ther. 2022;33(21\u201322):1126\u201341.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"1596_CR90","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","volume":"5","author":"M Abou-El-Enein","year":"2024","unstructured":"Abou-El-Enein M. The Fate(s) of CAR T-cell therapy: navigating the risks of CAR+ T-cell malignancy. Blood Cancer Discov. 2024;5(4):249\u201357.","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"1596_CR91","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;31(11):3123\u20136.","journal-title":"Mol Ther"},{"issue":"7","key":"1596_CR92","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","volume":"24","author":"RJ Ihry","year":"2018","unstructured":"Ihry RJ, et al. P53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24(7):939\u201346.","journal-title":"Nat Med"},{"key":"1596_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101272","volume":"71","author":"S Pagliuca","year":"2025","unstructured":"Pagliuca S, et al. The landscape of immune monitoring in CAR-T cell therapy: a comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT. Blood Rev. 2025;71: 101272.","journal-title":"Blood Rev"},{"key":"1596_CR94","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ebiom.2018.07.008","volume":"34","author":"M Hamada","year":"2018","unstructured":"Hamada M, et al. Integration mapping of piggyBac-mediated CD19 chimeric antigen receptor T cells analyzed by novel tagmentation-assisted PCR. EBioMedicine. 2018;34:18\u201326.","journal-title":"EBioMedicine"},{"key":"1596_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1259620","volume":"10","author":"M Iengo","year":"2023","unstructured":"Iengo M, et al. The broad spectrum of cardiotoxicities from immunotherapies. Front Cardiovasc Med. 2023;10: 1259620.","journal-title":"Front Cardiovasc Med"},{"key":"1596_CR96","doi-asserted-by":"publisher","first-page":"131617","DOI":"10.1016\/j.ijcard.2023.131617","volume":"398","author":"E Silver","year":"2024","unstructured":"Silver E, et al. Gene therapy vector-related myocarditis. Int J Cardiol. 2024;398:131617.","journal-title":"Int J Cardiol"},{"key":"1596_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1138596","volume":"11","author":"R Ewaisha","year":"2023","unstructured":"Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeutics-critical considerations for clinical translation. Front Bioeng Biotechnol. 2023;11: 1138596.","journal-title":"Front Bioeng Biotechnol"},{"issue":"25","key":"1596_CR98","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74(25):3099\u2013108.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1596_CR99","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00277-024-05640-z","volume":"103","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Zhu X, Xiao Y. The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. Ann Hematol. 2024;103(7):2197\u2013206.","journal-title":"Ann Hematol"},{"issue":"17","key":"1596_CR100","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","volume":"142","author":"S Ganatra","year":"2020","unstructured":"Ganatra S, et al. Chimeric antigen receptor T-cell therapy\u2013associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020;142(17):1687\u201390.","journal-title":"Circulation"},{"key":"1596_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1090103","author":"M Camilli","year":"2023","unstructured":"Camilli M, et al. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: a clinical appraisal. Front Cardiovasc Med. 2023. https:\/\/doi.org\/10.3389\/fcvm.2023.1090103.","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"1596_CR102","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood.2019003686","volume":"139","author":"E Porpaczy","year":"2022","unstructured":"Porpaczy E, J\u00e4ger U. How i manage autoimmune cytopenias in patients with lymphoid cancer. Blood. 2022;139(10):1479\u201388.","journal-title":"Blood"},{"issue":"2","key":"1596_CR103","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.7861\/clinmed.2020-0827","volume":"21","author":"R Hattersley","year":"2021","unstructured":"Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: a review. Clin Med (Lond). 2021;21(2):e212\u201322.","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"1596_CR104","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ando.2023.03.014","volume":"84","author":"F Albarel","year":"2023","unstructured":"Albarel F, Brue T, Castinetti F. Pituitary and adrenal disorders induced by immune checkpoint inhibitors. Ann Endocrinol. 2023;84(3):339\u201345.","journal-title":"Ann Endocrinol"},{"issue":"2","key":"1596_CR105","first-page":"35","volume":"23","author":"C Callahan","year":"2019","unstructured":"Callahan C, et al. Pediatric survivorship: considerations following CAR T-cell therapy. Clin J Oncol Nurs. 2019;23(2):35\u201341.","journal-title":"Clin J Oncol Nurs"},{"issue":"8","key":"1596_CR106","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16365","volume":"31","author":"R Bellanti","year":"2024","unstructured":"Bellanti R, Rinaldi S. Guillain-barr\u00e9 syndrome: a comprehensive review. Eur J Neurol. 2024;31(8): e16365.","journal-title":"Eur J Neurol"},{"key":"1596_CR107","unstructured":"(ICH), I.C.f.H.o.T.R.f.P.f.H.U., ICH Harmonised Guideline: S12 Nonclinical Biodistribution Considerations for Gene Therapy Products. Geneva. 2023."},{"issue":"2","key":"1596_CR108","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","volume":"5","author":"J Buechner","year":"2021","unstructured":"Buechner J, et al. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021;5(2):593\u2013601.","journal-title":"Blood Adv"},{"issue":"1","key":"1596_CR109","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1182\/hematology.2024000534","volume":"2024","author":"MR Bishop","year":"2024","unstructured":"Bishop MR. Late complications and long-term care of adult CAR T-cell patients. Hematology. 2024;2024(1):109\u201315.","journal-title":"Hematology"},{"issue":"7","key":"1596_CR110","first-page":"425","volume":"113","author":"S Crisafulli","year":"2022","unstructured":"Crisafulli S, Trifir\u00f2 G. The role of real-world evidence for the study of rare diseases epidemiology and the post-marketing evaluation of orphan drugs. Recent Prog Med. 2022;113(7):425\u20139.","journal-title":"Recent Prog Med"},{"issue":"1","key":"1596_CR111","doi-asserted-by":"publisher","first-page":"13641","DOI":"10.1038\/s41598-024-64466-x","volume":"14","author":"J Jung","year":"2024","unstructured":"Jung J, et al. A real-world pharmacovigilance study on cardiovascular adverse events of tisagenlecleucel using machine learning approach. Sci Rep. 2024;14(1):13641.","journal-title":"Sci Rep"},{"key":"1596_CR112","doi-asserted-by":"publisher","first-page":"1434231","DOI":"10.3389\/fphar.2024.1434231","volume":"15","author":"J Shi","year":"2024","unstructured":"Shi J, et al. CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017\u20132023). Front Pharmacol. 2024;15:1434231.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1596_CR113","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12916-024-03637-z","volume":"22","author":"Y Cai","year":"2024","unstructured":"Cai Y, et al. Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study. BMC Med. 2024;22(1):421.","journal-title":"BMC Med"},{"issue":"21","key":"1596_CR114","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414\u201324.","journal-title":"Blood Adv"},{"issue":"17","key":"1596_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179518","volume":"25","author":"S Bouziana","year":"2024","unstructured":"Bouziana S, Bouzianas D. The current landscape of secondary malignancies after CAR T-cell therapies: how could malignancies be prevented? Int J Mol Sci. 2024;25(17): 9518.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1596_CR116","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2378543","volume":"20","author":"D Goyco Vera","year":"2024","unstructured":"Goyco Vera D, et al. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother. 2024;20(1): 2378543.","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"1596_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/ph17081025","volume":"17","author":"Z Guo","year":"2024","unstructured":"Guo Z, et al. Comparing the differences in adverse events among chimeric antigen receptor T-cell therapies: a real-world pharmacovigilance study. Pharmaceuticals. 2024;17(8): 1025.","journal-title":"Pharmaceuticals"},{"issue":"22","key":"1596_CR118","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMp1809643","volume":"379","author":"R Platt","year":"2018","unstructured":"Platt R, et al. The FDA sentinel initiative\u2014an evolving national resource. N Engl J Med. 2018;379(22):2091\u20133.","journal-title":"N Engl J Med"},{"key":"1596_CR119","unstructured":"in The EBMT Handbook: Hematopoietic cell transplantation and cellular therapies, A. Sureda, et al., Editors. 2024, Springer. Copyright 2024, The Editor(s) (if applicable) and The Author(s). This book is an open access publication.: Cham (CH)."},{"key":"1596_CR120","unstructured":"Administration, U.S.F.a.D., Assessment in Support of the Sentinel System. 2022: Silver Spring, MD."},{"issue":"1","key":"1596_CR121","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpt.2479","volume":"111","author":"P Arlett","year":"2022","unstructured":"Arlett P, et al. Real-world evidence in EU medicines regulation: enabling use and establishing value. Clin Pharmacol Ther. 2022;111(1):21\u20133.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1596_CR122","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12961-025-01287-y","volume":"23","author":"J Peltner","year":"2025","unstructured":"Peltner J, et al. The EU project Real4Reg: unlocking real-world data with AI. Health Res Policy Syst. 2025;23(1):27.","journal-title":"Health Res Policy Syst"},{"key":"1596_CR123","unstructured":"https:\/\/www.fda.gov\/drugs\/risk-evaluation-and-mitigation-strategies-rems, F.R.E.a.M.S.O.a.R."},{"issue":"1","key":"1596_CR124","doi-asserted-by":"publisher","first-page":"25752","DOI":"10.1038\/s41598-024-77210-2","volume":"14","author":"HJ Park","year":"2024","unstructured":"Park HJ, et al. Patient-reported outcomes of chimeric antigen receptor T-cell therapy in hematologic malignancies: a systematic review and meta-analysis. Sci Rep. 2024;14(1):25752.","journal-title":"Sci Rep"},{"issue":"8","key":"1596_CR125","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/bcp.15791","volume":"89","author":"PA Routledge","year":"2023","unstructured":"Routledge PA, Bracchi R. Improving the spontaneous reporting of suspected adverse drug reactions: an overview of systematic reviews. Br J Clin Pharmacol. 2023;89(8):2377\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1596_CR126","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","volume":"22","author":"F Liu","year":"2022","unstructured":"Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22(1):287.","journal-title":"BMC Med Res Methodol"},{"key":"1596_CR127","doi-asserted-by":"publisher","first-page":"12302","DOI":"10.3389\/jpps.2024.12302","volume":"27","author":"K Zisis","year":"2024","unstructured":"Zisis K, et al. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process. J Pharm Pharm Sci. 2024;27:12302.","journal-title":"J Pharm Pharm Sci"},{"issue":"7","key":"1596_CR128","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.cell.2024.02.012","volume":"187","author":"K Verkerk","year":"2024","unstructured":"Verkerk K, Voest EE. Generating and using real-world data: a worthwhile uphill battle. Cell. 2024;187(7):1636\u201350.","journal-title":"Cell"},{"key":"1596_CR129","unstructured":"Agency EM. DARWIN EU\u00ae continues expanding its capacity to deliver real-world data studies. 2024."},{"key":"1596_CR130","unstructured":"Centre, U.M. VigiBase: WHO\u2019s global database signalling harm and pointing to safer use. 2025. https:\/\/who-umc.org\/vigibase\/vigibase-who-s-global-database\/. Accessed 24 Apr 2025."},{"issue":"2","key":"1596_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2024.101557","volume":"37","author":"C Chabannon","year":"2024","unstructured":"Chabannon C, et al. Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: collection of real-world data in the context of hematopoietic cellular therapies. Best Pract Res Clin Haematol. 2024;37(2): 101557.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1596_CR132","doi-asserted-by":"publisher","first-page":"1428831","DOI":"10.3389\/fdsfr.2024.1428831","volume":"4","author":"JV Kim","year":"2024","unstructured":"Kim JV, et al. Integrating electronic health records with other data sources for postmarket drug safety signal identification: a review. Front Drug Saf Regul. 2024;4:1428831.","journal-title":"Front Drug Saf Regul"},{"issue":"1","key":"1596_CR133","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/pds.5548","volume":"32","author":"A Coste","year":"2023","unstructured":"Coste A, et al. Methods for drug safety signal detection using routinely collected observational electronic health care data: a systematic review. Pharmacoepidemiol Drug Saf. 2023;32(1):28\u201343.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 2","key":"1596_CR134","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1038\/bmt.2008.290","volume":"42","author":"JM Cornish","year":"2008","unstructured":"Cornish JM. JACIE accreditation in paediatric haemopoietic SCT. Bone Marrow Transplant. 2008;42(Suppl 2):S82\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"1596_CR135","unstructured":"Ltd., E. 2024 Market Outlook for Cell & Gene Therapies. 2024. https:\/\/www.cellandgene.com\/doc\/2024-market-outlook-for-cell-gene-therapies-0001. Accessed 23 Apr 2025."},{"issue":"1","key":"1596_CR136","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/cpt.3087","volume":"115","author":"M Rohde","year":"2024","unstructured":"Rohde M, et al. Practical and statistical considerations for the long term follow-up of gene therapy trial participants. Clin Pharmacol Ther. 2024;115(1):139\u201346.","journal-title":"Clin Pharmacol Ther"},{"key":"1596_CR137","unstructured":"Agency EM. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10\u201313 June 2024. 2024. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024. Accessed 24 Apr 2025."},{"issue":"1","key":"1596_CR138","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11096-022-01461-0","volume":"45","author":"M Nakao","year":"2023","unstructured":"Nakao M, et al. Postmarketing all-case surveillance trends and contribution to safety measures of drugs approved in Japan: a cross-sectional survey in 1999\u20132019. Int J Clin Pharm. 2023;45(1):108\u201316.","journal-title":"Int J Clin Pharm"},{"key":"1596_CR139","unstructured":"(PMDA), P.a.M.D.A. risk management plan and postmarketing surveillance in Japan. 2023. https:\/\/www.pmda.go.jp\/english\/safety\/approach\/0002.html. Accessed 24 Apr 2025."},{"key":"1596_CR140","unstructured":"website., C.D.N.C.R.f.M.D.a.I.V.D.I.C.D. https:\/\/chinameddevice.com\/resources3\/nmpa-cfda-regulations-3\/. Accessed 24 Apr 2025."},{"key":"1596_CR141","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Points to consider for long-term follow-up of gene therapy products. PMDA website. Published March 27. https:\/\/www.pmda.go.jp\/files\/000241205.pdf. Accessed 27 Apr 2025."},{"key":"1596_CR142","unstructured":"(ICMR), I.C.o.M.R., Salient Features of the National Guidelines for Gene Therapy Product Development and Clinical Trials 2019: New Delhi."},{"issue":"1","key":"1596_CR143","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jtct.2023.10.006","volume":"30","author":"KO McNerney","year":"2024","unstructured":"McNerney KO, et al. Inspired symposium part 3: prevention and management of pediatric chimeric antigen receptor T cell-associated emergent toxicities. Transplant Cell Ther. 2024;30(1):38\u201355.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"1596_CR144","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10555-024-10227-1","volume":"44","author":"AW Rankin","year":"2024","unstructured":"Rankin AW, et al. Evolving strategies for addressing CAR T-cell toxicities. Cancer Metastasis Rev. 2024;44(1):17.","journal-title":"Cancer Metastasis Rev"},{"key":"1596_CR145","unstructured":"Administration, U.S.F.a.D. Decentralized Clinical Trials for Drugs, Biological Products, and Devices: Guidance for Industry, Investigators, and Other Stakeholders. 2023. https:\/\/www.fda.gov\/media\/167696\/download. Accessed 24 Apr 2025."},{"issue":"5","key":"1596_CR146","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"26","key":"1596_CR147","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"10254","key":"1596_CR148","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"15","key":"1596_CR149","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.3390\/ijms21155406","volume":"21","author":"B Jamet","year":"2020","unstructured":"Jamet B, et al. Functional imaging for therapeutic assessment and minimal residual disease detection in multiple myeloma. Int J Mol Sci. 2020;21(15):5406.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1596_CR150","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"8","key":"1596_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101158","volume":"4","author":"P Strati","year":"2023","unstructured":"Strati P, et al. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN\u03b3-expressing CD8 T cells. Cell Rep Med. 2023;4(8): 101158.","journal-title":"Cell Rep Med"},{"issue":"18","key":"1596_CR152","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"key":"1596_CR153","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"231","author":"DH Chand","year":"2021","unstructured":"Chand DH, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2021;231:265\u20138.","journal-title":"J Pediatr"},{"key":"1596_CR154","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","volume":"100","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol. 2019;100:3\u201311.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"1596_CR155","first-page":"S129","volume":"30","author":"M Wheeler","year":"2024","unstructured":"Wheeler M, Skiles JL, Rahrig AL. Thrombotic microangiopathy following CAR-T cell therapy successfully treated with eculizumab in a pediatric patient. Transpl Cell Ther Off Publ Am Soc Transpl Cell Ther. 2024;30(2):S129.","journal-title":"Transpl Cell Ther Off Publ Am Soc Transpl Cell Ther"},{"issue":"3","key":"1596_CR156","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74(3):560\u20136.","journal-title":"J Hepatol"},{"issue":"7","key":"1596_CR157","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834\u201341.","journal-title":"JAMA Neurol"},{"key":"1596_CR158","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba9188","author":"J Hordeaux","year":"2020","unstructured":"Hordeaux J, et al. Microrna-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aba9188.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1596_CR159","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","volume":"32","author":"B Vrellaku","year":"2024","unstructured":"Vrellaku B, et al. A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders. Mol Ther. 2024;32(10):3220\u201359.","journal-title":"Mol Ther"},{"issue":"5","key":"1596_CR160","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa2113206","volume":"386","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, et al. Betibeglogene Autotemcel gene therapy for non-\u03b2(0)\/\u03b2(0) genotype \u03b2-thalassemia. N Engl J Med. 2022;386(5):415\u201327.","journal-title":"N Engl J Med"},{"issue":"16","key":"1596_CR161","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson AA, et al. Gene therapy in patients with transfusion-dependent \u03b2-thalassemia. N Engl J Med. 2018;378(16):1479\u201393.","journal-title":"N Engl J Med"},{"issue":"3","key":"1596_CR162","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021;384(3):252\u201360.","journal-title":"N Engl J Med"},{"issue":"8","key":"1596_CR163","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706\u201318.","journal-title":"N Engl J Med"},{"issue":"5","key":"1596_CR164","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman CM, et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (endeavor). Ann Neurol. 2023;94(5):955\u201368.","journal-title":"Ann Neurol"},{"key":"1596_CR165","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.6812","author":"A DeVine","year":"2025","unstructured":"DeVine A, et al. The children\u2019s oncology group long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers: a review. JAMA Oncol. 2025. https:\/\/doi.org\/10.1001\/jamaoncol.2024.6812.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1596_CR166","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1182\/hematology.2023000422","volume":"2023","author":"R Epperly","year":"2023","unstructured":"Epperly R, Shah NN. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. Hematology. 2023;2023(1):77\u201383.","journal-title":"Hematology"},{"key":"1596_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122685","volume":"348","author":"T Mohammadian Gol","year":"2024","unstructured":"Mohammadian Gol T, et al. Gene therapy in pediatrics\u2014clinical studies and approved drugs (as of 2023). Life Sci. 2024;348: 122685.","journal-title":"Life Sci"},{"key":"1596_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104337","author":"K de Haart","year":"2025","unstructured":"de Haart K, et al. Long-term follow-up after authorization of gene therapy: leveraging real-world data. Drug Discov Today. 2025. https:\/\/doi.org\/10.1016\/j.drudis.2025.104337.","journal-title":"Drug Discov Today"},{"issue":"16_suppl","key":"1596_CR169","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1200\/JCO.2024.42.16_suppl.10016","volume":"42","author":"RH Rouce","year":"2024","unstructured":"Rouce RH, et al. Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL): center for international blood & marrow transplant research (CIBMTR) registry results. J Clin Oncol. 2024;42(16_suppl):10016\u201310016.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1596_CR170","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297\u2013316.","journal-title":"Haematologica"},{"issue":"12","key":"1596_CR171","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1111\/bcp.15119","volume":"88","author":"B Aurich","year":"2022","unstructured":"Aurich B, et al. C4c: paediatric pharmacovigilance: methodological considerations in research and development of medicines for children - a C4c expert group white paper. Br J Clin Pharmacol. 2022;88(12):4997\u20135016.","journal-title":"Br J Clin Pharmacol"},{"key":"1596_CR172","unstructured":"Administration, U.S.F.a.D. International Collaboration\/Pediatric Cluster. 2024. https:\/\/www.fda.gov\/science-research\/pediatrics\/international-collaboration-pediatric-cluster. Accessed 24 Apr 24."},{"key":"1596_CR173","unstructured":"Institute, N.C. National Childhood Cancer Registry (NCCR). 2024. https:\/\/nccrexplorer.ccdi.cancer.gov\/. Accessed 1 May 2025."},{"key":"1596_CR174","unstructured":"Hospital, S.J.C.s.R. SJCARES Registry. 2024. https:\/\/www.stjude.org\/global\/sjcares\/registry.html. Accessed 1 May 2025."},{"key":"1596_CR175","unstructured":"(NAPAAC), N.A.P.A.A.C. North American Pediatric Aplastic Anemia Consortium. 2024. https:\/\/www.napaac.org. Accessed 1 May 2025."},{"issue":"1","key":"1596_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-022-04917-2","volume":"23","author":"Z Wei","year":"2022","unstructured":"Wei Z, et al. Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk. BMC Bioinform. 2022;23(1): 373.","journal-title":"BMC Bioinform"},{"key":"1596_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2023.102701","volume":"146","author":"J-A Sim","year":"2023","unstructured":"Sim J-A, et al. Natural language processing with machine learning methods to analyze unstructured patient-reported outcomes derived from electronic health records: a systematic review. Artif Intell Med. 2023;146: 102701.","journal-title":"Artif Intell Med"},{"key":"1596_CR178","doi-asserted-by":"publisher","first-page":"1080715","DOI":"10.3389\/fdata.2022.1080715","volume":"5","author":"X Fu","year":"2023","unstructured":"Fu X, et al. 3D bi-directional transformer U-Net for medical image segmentation. Front Big Data. 2023;5:1080715.","journal-title":"Front Big Data"},{"issue":"1","key":"1596_CR179","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-024-05804-8","volume":"25","author":"Z Wei","year":"2024","unstructured":"Wei Z, et al. PrCRS: a prediction model of severe CRS in CAR-T therapy based on transfer learning. BMC Bioinform. 2024;25(1): 197.","journal-title":"BMC Bioinform"},{"key":"1596_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2023.104367","volume":"142","author":"A Bogatu","year":"2023","unstructured":"Bogatu A, et al. Meta-analysis informed machine learning: supporting cytokine storm detection during CAR-T cell therapy. J Biomed Inform. 2023;142: 104367.","journal-title":"J Biomed Inform"},{"key":"1596_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109137","volume":"182","author":"A Boretti","year":"2024","unstructured":"Boretti A. The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy. Comput Biol Med. 2024;182: 109137.","journal-title":"Comput Biol Med"},{"issue":"6","key":"1596_CR182","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s12325-024-02870-5","volume":"41","author":"R De Abreu Ferreira","year":"2024","unstructured":"De Abreu Ferreira R, et al. A pilot, predictive surveillance model in pharmacovigilance using machine learning approaches. Adv Ther. 2024;41(6):2435\u201345.","journal-title":"Adv Ther"},{"key":"1596_CR183","unstructured":"XIV., CWG. Artificial intelligence in pharmacovigilance: draft report for public consultation. Council for International Organizations of Medical Sciences (CIOMS). 2025. https:\/\/cioms.ch\/wp-content\/uploads\/2022\/05\/CIOMS-WG-XIV_Draft-report-for-Public-Consultation_1May2025.pdf."},{"key":"1596_CR184","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2023-181936","volume":"142","author":"S Rajeeve","year":"2023","unstructured":"Rajeeve S, et al. Early and consistent CRS detection using wearable device for remote patient monitoring following CAR-T therapy in relapsed\/refractory multiple myeloma (rrmm): early results of an investigator-initiated trial. Blood. 2023;142:1007.","journal-title":"Blood"},{"key":"1596_CR185","unstructured":"EJ T. The Topol Review: preparing the healthcare workforce to deliver the digital future. NHS Health Education England. 2019. https:\/\/topol.hee.nhs.uk\/wp-content\/uploads\/HEE-Topol-Review-2019.pdf."},{"issue":"16_suppl","key":"1596_CR186","doi-asserted-by":"publisher","first-page":"e13626","DOI":"10.1200\/JCO.2023.41.16_suppl.e13626","volume":"41","author":"S Rajeeve","year":"2023","unstructured":"Rajeeve S, et al. Early detection of CRS after CAR-T therapy using wearable monitoring devices: preliminary results in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):e13626\u2013e13626.","journal-title":"J Clin Oncol"},{"key":"1596_CR187","doi-asserted-by":"publisher","DOI":"10.2196\/55918","volume":"8","author":"L Hurtado","year":"2024","unstructured":"Hurtado L, et al. Telemedicine with wearable technologies in patients undergoing hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy (TEL-HEMATO study): prospective noninterventional single-center study. JMIR Form Res. 2024;8: e55918.","journal-title":"JMIR Form Res"},{"key":"1596_CR188","doi-asserted-by":"publisher","DOI":"10.2196\/49089","volume":"26","author":"MB Perry","year":"2024","unstructured":"Perry MB, et al. Examining the effectiveness of electronic patient-reported outcomes in people with cancer: systematic review and meta-analysis. J Med Internet Res. 2024;26: e49089.","journal-title":"J Med Internet Res"},{"issue":"1","key":"1596_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01189-3","volume":"7","author":"Z Hussain","year":"2024","unstructured":"Hussain Z, et al. Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma. NPJ Digit Med. 2024;7(1): 200.","journal-title":"NPJ Digit Med"},{"issue":"11","key":"1596_CR190","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005459","volume":"10","author":"Y Amidi","year":"2022","unstructured":"Amidi Y, et al. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. J Immunother Cancer. 2022;10(11): e005459.","journal-title":"J Immunother Cancer"},{"key":"1596_CR191","unstructured":"Administration, U.S.F.a.D. Using artificial intelligence and machine learning in the development of drug and biological products. 2023. https:\/\/www.fda.gov\/media\/167973\/download. Accessed 28 Apr 2025."},{"issue":"1","key":"1596_CR192","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40364-020-00190-8","volume":"8","author":"M Du","year":"2020","unstructured":"Du M, et al. Biomarkers in individualized management of chimeric antigen receptor T cell therapy. Biomark Res. 2020;8(1):13.","journal-title":"Biomark Res"},{"issue":"1","key":"1596_CR193","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"key":"1596_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2023.115387","volume":"235","author":"SS Arya","year":"2023","unstructured":"Arya SS, et al. The convergence of traditional and digital biomarkers through AI-assisted biosensing: a new era in translational diagnostics? Biosens Bioelectron. 2023;235: 115387.","journal-title":"Biosens Bioelectron"},{"key":"1596_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.012","author":"J Luo","year":"2025","unstructured":"Luo J, Solit DB. Leveraging real-world data to advance biomarker discovery and precision oncology. Cancer Cell. 2025. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.012.","journal-title":"Cancer Cell"},{"issue":"5","key":"1596_CR196","first-page":"428","volume":"10","author":"PR Lowenstein","year":"2008","unstructured":"Lowenstein PR. Clinical trials in gene therapy: ethics of informed consent and the future of experimental medicine. Curr Opin Mol Ther. 2008;10(5):428\u201330.","journal-title":"Curr Opin Mol Ther"},{"issue":"7","key":"1596_CR197","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41588-020-0651-0","volume":"52","author":"L Bonomi","year":"2020","unstructured":"Bonomi L, Huang Y, Ohno-Machado L. Privacy challenges and research opportunities for genomic data sharing. Nat Genet. 2020;52(7):646\u201354.","journal-title":"Nat Genet"},{"issue":"2","key":"1596_CR198","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/jlme.12060","volume":"41","author":"MA Rothstein","year":"2013","unstructured":"Rothstein MA. HIPAA privacy rule 2.0. J Law Med Ethics. 2013;41(2):525\u20138.","journal-title":"J Law Med Ethics"},{"key":"1596_CR199","unstructured":"S\u00fcwer S, Probul N, Maier A, Baumbach J. Privacy-by-design with federated learning will drive future rare disease research. J Neuromuscular Dis. 2014."},{"issue":"6136","key":"1596_CR200","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1126\/science.1240156","volume":"340","author":"AL McGuire","year":"2013","unstructured":"McGuire AL, et al. Point-counterpoint. Ethics and genomic incidental findings. Science. 2013;340(6136):1047\u20138.","journal-title":"Science"},{"issue":"1","key":"1596_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05188-3","volume":"9","author":"KG Claw","year":"2018","unstructured":"Claw KG, et al. A framework for enhancing ethical genomic research with Indigenous communities. Nat Commun. 2018;9(1): 2957.","journal-title":"Nat Commun"},{"issue":"2","key":"1596_CR202","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/ejhg.2014.71","volume":"23","author":"J Kaye","year":"2015","unstructured":"Kaye J, et al. Dynamic consent: a patient interface for twenty-first century research networks. Eur J Hum Genet. 2015;23(2):141\u20136.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"1596_CR203","doi-asserted-by":"publisher","first-page":"11","DOI":"10.46989\/001c.115793","volume":"6","author":"K Gatwood","year":"2024","unstructured":"Gatwood K, et al. Outpatient CAR T-cell therapy as standard of care: current perspectives and considerations. Clin Hematol Int. 2024;6(2):11\u201320.","journal-title":"Clin Hematol Int"},{"key":"1596_CR204","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1090103","volume":"10","author":"M Camilli","year":"2023","unstructured":"Camilli M, et al. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: a clinical appraisal. Front Cardiovasc Med. 2023;10: 1090103.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"1596_CR205","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332.","journal-title":"Nat Med"},{"issue":"5","key":"1596_CR206","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455\u201364.","journal-title":"N Engl J Med"},{"issue":"7","key":"1596_CR207","first-page":"682","volume":"24","author":"KB Sonawane","year":"2018","unstructured":"Sonawane KB, Cheng N, Hansen RA. Serious adverse drug events reported to the FDA: analysis of the FDA adverse event reporting system 2006\u20132014 database. J Manag Care Spec Pharm. 2018;24(7):682\u201390.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7785","key":"1596_CR208","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149\u201357.","journal-title":"Nature"},{"issue":"8","key":"1596_CR209","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765\u201371.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1596_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41004-3","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang C, et al. Prediction of base editor off-targets by deep learning. Nat Commun. 2023;14(1): 5358.","journal-title":"Nat Commun"},{"key":"1596_CR211","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.omtm.2020.03.006","volume":"17","author":"N Khan","year":"2020","unstructured":"Khan N, et al. AAV6 vexosomes mediate robust suicide gene delivery in a murine model of hepatocellular carcinoma. Mol Ther Methods Clin Dev. 2020;17:497\u2013504.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"1596_CR212","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, et al. CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transplant. 2025;60(1):6\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1596_CR213","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2022.874251","volume":"4","author":"H Kipruto","year":"2022","unstructured":"Kipruto H, et al. Use of digital health interventions in sub-Saharan Africa for health systems strengthening over the last 10 years: a scoping review protocol. Front Digit Health. 2022;4: 874251.","journal-title":"Front Digit Health"},{"issue":"1","key":"1596_CR214","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/hae.14190","volume":"27","author":"E van Overbeeke","year":"2021","unstructured":"van Overbeeke E, et al. Patient perspectives regarding gene therapy in haemophilia: interviews from the PAVING study. Haemophilia. 2021;27(1):129\u201336.","journal-title":"Haemophilia"},{"issue":"1","key":"1596_CR215","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02576-3","volume":"18","author":"T Collin-Histed","year":"2023","unstructured":"Collin-Histed T, et al. Understanding patient and parent\/caregiver perceptions on gene therapy in Gaucher disease: an international survey. Orphanet J Rare Dis. 2023;18(1): 5.","journal-title":"Orphanet J Rare Dis"},{"issue":"23\u201324","key":"1596_CR216","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1089\/hum.2023.157","volume":"34","author":"L Kimberly","year":"2023","unstructured":"Kimberly L, et al. The lived experience of pediatric gene therapy: a scoping review. Hum Gene Ther. 2023;34(23\u201324):1180\u20139.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"1596_CR217","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","volume":"30","author":"K Cornetta","year":"2022","unstructured":"Cornetta K, et al. Gene therapy access: global challenges, opportunities, and views from Brazil, South Africa, and India. Mol Ther. 2022;30(6):2122\u20139.","journal-title":"Mol Ther"},{"issue":"10","key":"1596_CR218","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1200\/OP.24.00270","volume":"20","author":"TL Kaufmann","year":"2024","unstructured":"Kaufmann TL, Rocque GB. Using electronic patient-reported outcome monitoring to navigate patients to supportive care services. JCO Oncol Pract. 2024;20(10):1297\u20139.","journal-title":"JCO Oncol Pract"},{"key":"1596_CR219","doi-asserted-by":"publisher","first-page":"1257732","DOI":"10.3389\/fdsfr.2023.1257732","volume":"3","author":"TA Hammad","year":"2023","unstructured":"Hammad TA, et al. Navigating a transforming landscape: the evolving role of pharmacovigilance physicians in drug development and implications for future challenges and training requirements. Front Drug Saf Regul. 2023;3:1257732.","journal-title":"Front Drug Saf Regul"},{"key":"1596_CR220","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2024.1356405","author":"S Crisafulli","year":"2024","unstructured":"Crisafulli S, et al. Artificial intelligence for optimizing benefits and minimizing risks of pharmacological therapies: challenges and opportunities. Front Drug Saf Regul. 2024. https:\/\/doi.org\/10.3389\/fdsfr.2024.1356405.","journal-title":"Front Drug Saf Regul"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01596-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01596-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01596-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:02:48Z","timestamp":1768374168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01596-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":220,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01596-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"23 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors are employed by Kapadi, a contract research organization (CRO).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors contributed to the conceptualization, writing, and revision of the manuscript. All authors have read and approved the final version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}},{"value":"Not applicable. This article is a narrative review based entirely on previously published literature and does not involve any new studies with human participants, animals, or identifiable data. Therefore, institutional ethics approval or consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. This review does not involve any original research with human participants; thus, no participant consent was necessary.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. This article does not include any individual data or images requiring consent for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material:"}},{"value":"Not applicable. No custom code or software applications were used in the preparation of this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}